News and Comments

Companies Targeted for Takeover Yet Can Thrive on their Own

  Thursday, February 02, 2017

It seems that the global Takeda (TKPYY) has guessed well what it should pick in order to bring the most effective targeted treatments to cancer patients allover the globe. Cancer management has unreservedly changed. What seems now to have become the best treatment choices are those that would accommodate the new wave of extremely promising immunotherapy approaches.     More...

Exelixis: Results Demonstrate the Potential of Cabozantinib to Become the Gold Standard First Line Treatment for Advanced RCC

  Monday, May 23, 2016

Yes, indeed, the good news has come from the randomized CABOSUN phase 2 trial with Exelixis’ (EXEL) drug cabozantinib. The news is indirectly telling us that Cabozantinib may soon become the first-line treatment for previously untreated advanced renal cell carcinoma (RCC).  More...

The FDA Approval of Exelixis Drug Cabometyx™ Is Indeed Great News

  Tuesday, April 26, 2016

Congratulation.   More...

One Year Accomplishments Vs. One Cent Missed in Agenus Financial Report

  Thursday, March 03, 2016

Agenus (AGEN) is a project in the making since the firm has decided to play an integral part in immuno-oncology, doing everything possible towards building checkpoint modulator antibodies, in addition to its protective and therapeutic vaccines.    More...

Exelixis: Great News Towards Great Changes

  Tuesday, March 01, 2016

Exelixis’ (EXEL) quarterly results beat analysts’ expectations, which was the least of our concerns. The details of the firm’s actions during the past year, however, confirmed our conviction that the recently approved products will be taken care of responsibly by the firm that created them and believed in them against all pessimistic opinions.  More...

Exeixis Will Begin Reaping the Fruits

  Tuesday, November 10, 2015


The Stream of Exelixis Good News is Real

  Thursday, October 22, 2015


Why Switzerland Approval of Exelixis and Roche Drug Combination for melanoma is a Big Deal?

  Thursday, August 27, 2015


EXELEXIS: The Importance Of The Public Offering. XOMA: What Should We Do Now?

  Thursday, July 23, 2015

Why the financing through a secondary public offering was a must for Exelixis?  More...


  Wednesday, July 16, 2014

We stayed with Exelixis (EXEL) In spite of the negative articles that made this firm look as if planting seeds in the ocean. Investors acted as if condemning the firm’s efforts, its small molecule drug design technology and its investigational oncology products. We remained fans in spite of the complete paralysis of the stock for a long time. We always believed that all the negatives about this firm measure little compared to its positives. More...

Recent Postings



Mirati Therapeutics (MRTX) galapagos (GLPG) Sanofi (SNY) Idenix (IDIX) KERYX (KERX) MODERNA Dynavax (DVAX) INNOVIVA (INVA) PTC Therapeutics (PTCT) Vitae Pharmaceuticals (VTAE) Zerenex Sequenom (SQNM) Benlysta (belimumab) GlaxoSmithKline (GSK) ARCA (ABIO) Roche (ROCHE) GUARDIAN HEALTH C4 Therapeutics Spike Therapeutics (ONCE) Alder Biopharmaceuticals (ALDR) BIOMARIN (BMRN) JOUNCE THERAPEUTICS (JNCE) ISIS (ISIS) ImmunoGen (IMGN) Intrexon (XON) Amgen (AMGN) Auspex (ASPX) Theravance (THRX) IDERA (IDRA) Illumina (ILMN) Bristol-Myers Squibb (BMY) Revlimid (lenolidamide) Xoma (XOMA) Incyte (INCY) ACADIA (ACAD) NEKTAR (NKTR)) Alnylam (ALNY) KITE (KITE) NANTKWEST (NK) Adaptimmune (ADAP) SUNESIS PHARMACEUTICALS (SNSS) RenenxBio (RGNX) CRISPR Therapeutics (CRSP) Merck (MRK) Prolor Biotech (PBTH) SYNTA (SNTA) Intermune (ITMN) Sangamo (SGMO) Intercept (ICPT) Ionis (IONS) HALOZYME (HALO) OSI (OSIP) Biocryst (BCRX) Global Cell Therapeutics (GBT) SERES THERAPEUTICS (MCRB) REGULUS (RGLS) ADVENTRIX (ANX) Anadys (ANDS) Human Genome Sciences (HGSI) Dendreon (DNDN) Valeant Pharmaceuticals International (VRX) VANDA (VNDA) Telaprevir Ariad (ARIA) Ocular Therapeutix (OCUL) Roche (RHHBY) Regeneron (REGN) Biogen Idec (BIIB) Galena (GALE) Agenus (AGEN) Genentech NOVOCURE (NVCR) Sarepta (SRPT) Trastuzumab-DM1 Sanofi-Aventis (SAN) Theravance Bio Pharma (TBPH) Onyx (ONXX) Velcade (bortezomib) JUNO (JUNO) ABBVIE (ABBV) Inovio (INO) Bellicum (BLCM) CompuGen (CGEN) Elan (ELN) Anacor (ANAC) Human Longevity (HLI) Gilead (GILD) CEMPRA (CEMP) Endometrial Cancer Jazz Pharmaceuticals (JAZZ) Tysabri Rapamune Abbott Laboratories (ABT) Herceptin Advaxis (ADXS) Aimmune Therapeutics (AIMT) ARGOS (ARGS) AstraZeneca (AZN) TOKAI (TKAOI) AERIE PHARMACEUTICALS Prosensa (RNA) Editas (EDIT) Cytokinetics (CYTK) Seattle Genetics (SGEN) Multiple Myeloma ZALTRAP™ Array Pharmaceuticals (ARRY) Vertex (VRTX) Ziofpharm (ZIOP) PORTOLA (PTLA) Micromet (MITI) Exelixis (EXEL) Agenus (AGEN Sanofi (SNA) Ridaforolimus Pluristem (PSTI) AGOS (ARGS)